ClinicalTrials.gg
RecruitingNCT07552116interventionUpdated Apr 27, 2026

Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia

An interventional study of low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements and received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. in Pneumonia, sponsored by Badr University. Recruiting at 1 site in Egypt. Open to participants aged 3 Years to 5 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Badr University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
3 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Pneumonia with a site in Egypt — 9 open to participants now, 11 under way, 1 of them phase 3. Pneumonia · Egypt.

Planned enrollment
23rd of 26
40 · median 70
Started
2026
with 2 others
No phase
20 of 39
4 open now
Primary completion
2026-05
later than 6 of 10 live
Registered
38th of 39
by date
Lead sponsor
2 of 39
Badr University

Among the 39 studies in Pneumonia with a site in Egypt, this one is the 23rd largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2026, is one of 20 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 38th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

9 of the 39 studies in Pneumonia with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 3 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Pneumonia with a site in Egypt, or all of them as a file.
02

Study summary

Objective: The aim of this study was to detect the impact of low intensity laser therapy on immune system response among DS children with pneumonia. Material and Methods: Forty DS children with bronchopneumonia, were included into ; group (A) received low intensity laser therapy, inspiratory muscle training in addition to medical treatment at a frequency of 3 sessions per week for one month, where the second group (B) received inspiratory muscle training in addition to medical treatment. Measurements of WBCs, IgG, IgA, IgM, RR and SaO2 were obtained for both groups before treatment and after one month at the end of the treatment program.

Read the detailed description

The aim of this study was to detect the impact of low intensity laser therapy on immune system response among DS children with pneumonia. Material and Methods: Forty DS children with bronchopneumonia, mean age of 3.73±1.82 year and were included into 2 equal groups; group (A) received low intensity laser therapy, inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment at a frequency of 3 sessions per week for one month, where the second group (B) received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements of WBCs, IgG, IgA, IgM, RR and SaO2 were obtained for both groups before treatment and after one month at the end of the treatment program.

03

Conditions studied

  • Pneumonia

Browse trials for

Keywords

  • Laser, Immune, Pneumonia, Dawn syndrome
04

Who can participate

Ages eligible
3 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dawn Syndrome children with pneumonia
  • Mean age of 3.73±1.82 year
  • Children were in the first attack of bronchopneumonia.

Exclusion criteria

Exclusion Criteria:

  • Other chest disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    group (A)

    received low intensity laser therapy, inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment at a frequency of 3 sessions per week for one month

    Other: low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements · Other: received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

  • Experimental
    group (B)

    received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

    Other: received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

Interventions

  • Otherlow intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements

    low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements

    Also known as: low intensity laser therapy, muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements

  • Otherreceived inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

    received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

    Also known as: inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

06

What researchers measure

Primary outcomes

  1. IgG

    Immunoglobulin-G (mg/dl)

    Time frame: at baseline and after one month

  2. IgA

    Immunoglobulin-A(mg/dl)

    Time frame: at baseline and after one month

  3. IgM

    Immunoglobulin-M (mg/dl)

    Time frame: at baseline and after one month

  4. WBCs

    White blood cells (thousands/mm3)

    Time frame: at baseline and after one month

Secondary outcomes

  1. RR

    Respiratory Rate(breath/minute)

    Time frame: at baseline and after one month

  2. SaO2

    Arterial oxygen saturation(%)

    Time frame: at baseline and after one month

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2026, 1 month after the start.

Of 260 non-industry interventional studies with no phase under Pneumonia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 1 month is below that.

Counting every sponsor, half of 267 studies reached it within 22 months; a quarter within 11 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 27, 2026
StartActual
Apr 6, 2026
Primary completionEst.
May 30, 2026
CompletionEst.
May 30, 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07552116
Lead sponsor
Badr University
Responsible party
Mona Mohamed Abdelkhalek (assistance professor, Badr University) — Principal investigator
First posted
Apr 27, 2026
Start date
Apr 6, 2026
Primary completion
May 30, 2026 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Apr 27, 2026

Study contacts

Mona Mohamed Abdelkhalek, assistance professor
Contact
mona.abdelkhalek@buc.edu.eg
00201024056108
Mona Mohamed Abdelkhalek, assistance professor
Contact
3m.sons@gmail.com
00201024056108
Mona Mohamed Abdelkhalek, assistance prof
principal investigator · Badr University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion